Prostate Cancer Therapeutics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Prostate Cancer Therapeutics Market By Drug Class (Chemotherapeutic agents, Immune System Modulators, Hormones, Others), By Route Of Administration (Oral, Parenteral, Other), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others), and Geography 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Prostate Cancer Therapeutics Market size was valued at USD 11.14 billion in 2021, growing at a CAGR of 6.6% during the forecast period 2022-2028. The prostate is an exocrine gland and found only in males.  Prostate cancer begins when cells in the prostate gland start to grow uncontrollably. It may spread to other parts of the body mainly bones and lymph nodes. Prostate cancer is the most common type of cancer among men, but often it can be treated successfully, in initial stages it shows no symptoms but later stages it may produce pain in pelvis, difficulty in urination and furthermore, it may cause tiredness and low levels of RBC. The exact cause of prostate cancer is unknown but are generally linked to hereditary causes or to unhealthy diet and lifestyle. Studies suggest that high consumption of red meat and processed meat increases the chances of prostate cancer. Primary risk factors for prostate cancer include obesity, age and family history. Prostate cancer can be diagnosed by biopsy, prostate imaging and various other techniques. New tests such as phi test, 4Kscore test, Progensa, TMPRSS2 ERG and ConfirmMDX will be more accurate in early-stage diagnosis. This, in turn, aids in increasing the diagnosis rate and consecutively aid in the growth of the market. Prostate cancer therapeutics market has large and small players and the market is highly competitive. Players adopting acquisitions, mergers and collaborations to stenghten product offerings in prostate therapeutics market.

Key Developments:

On September 17, 2019 FDA approved Apalutamide (ERLEADA, Janssen Biotech, Inc) for metastatic castration – sensitive prostate cancer (mCSPC)

In 2016, October, U.S. FDA approved a supplemental new drug application for XTANDI (enzalutamide) capsules of Astellas Pharma Inc. & Pfizer Inc. to treat patients with metastatic xastration resistance prostate cancer

In 2011, Johnson & Johnson has received U.S. FDA approval for ZytIGA used to treat metastatic prostate cancer.

Prostate Cancer Therapeutics Market

MARKET SUMMARY
-
6.6% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 6.6%
  • Largest Market– North America
  • Fastest Growing Market–  Asia Pacific

Prostate Cancer Therapeutics Market

  • The report on global prostate cancer therapeutics market gives historical, current and future market sizes (US$ Mn) on the basis of by drug class, by route of administration, distribution channel and geography.
  • The prostate cancer therapeutics market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Johnson & Johnson Services Inc. (U.S.)
  • AbbVie, Inc.(U.S.)
  • Amgen, Inc.(U.S.)
  • AstraZeneca (U.K)
  • Ipsen Group(France)
  • Sanofi (France)
Prostate Cancer Therapeutics Market Dynamics

prostate cancer therapeutics market is rapidly growing due to increase in incidence of prostate cancer and increase in ageing population. In addition, technological advancements in prostate cancer treatment such as radiation therapy and targeted therapy are expected to boost the prostate cancer therapeutics market. However, patients in underdeveloped and developing regions cannot afford the high costs of treatment and diagnosis of cancer can hinder market growth. In addition to this, low diagnostic rates due to unawareness about prostate cancer symptoms is hampering the prostate cancer therapeutics market.


North-America got significant share

Prostate Cancer Therapeutics Market

Geographically prostate cancer drugs market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America expected to have major market share owing to increased research and development, developed healthcare infrastructure and high rate of prostate cancer incidents. In 2017, the American Cancer Society predicts that there will be around 161,360 new diagnoses of prostate cancer and that around 26,730 fatalities will occur because of prostate cancer in America alone. Europe is anticipated to grow at significant rates due to increase in prevalence rates and developed healthcare infrastructure facilities. Asia Pacific region expected to be fastest growing due to developing healthcare infrastructure facilities and increased research and development focused on cancer therapeutics.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share and forecast from 2022-2028
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Prostate Cancer Therapeutics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The prostate cancer therapeutics market is projected to expand at a CAGR of 6.6% during the forecast period

Johnson & Johnson Services Inc. (U.S.), AbbVie, Inc.(U.S.), Amgen, Inc.(U.S.), AstraZeneca (U.K), Ipsen Group(France), Sanofi (France)

North America is the fastest-growing region for prostate cancer therapeutics market


Report

Table Of Content


Report

Company Profile

  • Johnson & Johnson Services Inc. (U.S.)
  • AbbVie, Inc.(U.S.)
  • Amgen, Inc.(U.S.)
  • AstraZeneca (U.K)
  • Ipsen Group(France)
  • Sanofi (France)
  • Dendreon Corporation (Sanpower Group Co. Ltd.) (U.S.)
  • Bayer AG (Germany)
  • Endo Pharmaceuticals, Inc. (U.S)
  • Pfizer, Inc (U.S.)

Description

Prostate Cancer Therapeutics Market size was valued at USD 11.14 billion in 2021, growing at a CAGR of 6.6% during the forecast period 2022-2028. The prostate is an exocrine gland and found only in males.  Prostate cancer begins when cells in the prostate gland start to grow uncontrollably. It may spread to other parts of the body mainly bones and lymph nodes. Prostate cancer is the most common type of cancer among men, but often it can be treated successfully, in initial stages it shows no symptoms but later stages it may produce pain in pelvis, difficulty in urination and furthermore, it may cause tiredness and low levels of RBC. The exact cause of prostate cancer is unknown but are generally linked to hereditary causes or to unhealthy diet and lifestyle. Studies suggest that high consumption of red meat and processed meat increases the chances of prostate cancer. Primary risk factors for prostate cancer include obesity, age and family history. Prostate cancer can be diagnosed by biopsy, prostate imaging and various other techniques. New tests such as phi test, 4Kscore test, Progensa, TMPRSS2 ERG and ConfirmMDX will be more accurate in early-stage diagnosis. This, in turn, aids in increasing the diagnosis rate and consecutively aid in the growth of the market. Prostate cancer therapeutics market has large and small players and the market is highly competitive. Players adopting acquisitions, mergers and collaborations to stenghten product offerings in prostate therapeutics market.

Key Developments:

On September 17, 2019 FDA approved Apalutamide (ERLEADA, Janssen Biotech, Inc) for metastatic castration – sensitive prostate cancer (mCSPC)

In 2016, October, U.S. FDA approved a supplemental new drug application for XTANDI (enzalutamide) capsules of Astellas Pharma Inc. & Pfizer Inc. to treat patients with metastatic xastration resistance prostate cancer

In 2011, Johnson & Johnson has received U.S. FDA approval for ZytIGA used to treat metastatic prostate cancer.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX